Latest filingSep 01, 2026Most recent Form 4
AVTX
Avalo Therapeutics, Inc.
NasdaqHealthcarePharmaceutical Preparations
Insider activity for last month from 08/03 to 09/03. Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.
Total buying$00 buys
Total selling$148M5 sells
Net open-market-$148M2 insiders
Open-market mix
Buy vs sell distribution by transaction countInsider activity report
Monthly open-market purchase and sale counts Buys Sells
Transaction codes
By Form 4 transaction code in selected period15transactions
- M · Option exercise · dominant10 · 67%
- S · Open-market sells5 · 33%
Activity by reported role
A joint filing can contribute to multiple roles15transactions
- Chief financial officer · dominant9 · 60%
- CMO6 · 40%
Distinct insiders active
Reporting-owner CIKs by month · peak Aug 2026 (2)Aug 2026Sep 2026
Reported Holdings After
Separated by insider, security, and ownership typeSullivan Christopher RyanCommon Stock · Direct
39,900Aug 18, 2026
Doyle MittieCommon Stock · Direct
51,776Aug 28, 2026
Sullivan Christopher RyanStock Option (Right to Buy) · Direct
96,242Aug 18, 2026
Doyle MittieStock Option (Right to Buy) · Direct
113,734Aug 28, 2026
These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.
Filing activity heatmap
Each cell is one day · intensity = transactions · buys green, sells redAug 03 → Sep 03
LessMore
Top insiders
By absolute net value across the selected period- SR-$740.5k
- DM-$15.5k
Recent filing activity
Most recent 12 transactions · color = transaction code- MOption exercise09/01$0SEC
- SSell09/01-$1.35MSEC
- MOption exercise09/01$545kSEC
- MOption exercise08/19$0SEC
- MOption exercise08/19$0SEC
- MOption exercise08/19$0SEC
- SSell08/19-$62.2MSEC
- MOption exercise08/19$30.6MSEC
- SSell08/19-$7.47MSEC
- SSell08/19-$75.3MSEC
- MOption exercise08/19$2.84MSEC
- MOption exercise08/19$37.4MSEC
Filing detail checks
Secondary metrics for the selected periodFiling-only signals
Deterministic matches in the selected period
AVTX transaction history
Filters apply within this company and selected period by default| Ticker | Insider | Role | Type | Shares | Value | Code | Signals | 90d return | Filed | Trans date |
|---|---|---|---|---|---|---|---|---|---|---|
| AVTX | Doyle Mittie | CMO | exercise10b5-1 | 679 | $0 | M | 0.0% | 09/01 | 08/28 | |
| AVTX | Doyle Mittie | CMO | sale10b5-1 | 679 | -$1.35M | S | 0.0% | 09/01 | 08/28 | |
| AVTX | Doyle Mittie | CMO | exercise10b5-1 | 679 | $545k | M | 0.0% | 09/01 | 08/28 | |
| AVTX | Sullivan Christopher Ryan | CFO | exercise10b5-1 | 31.0k | $0 | M | −8.7% | 08/19 | 08/18 | |
| AVTX | Sullivan Christopher Ryan | CFO | exercise10b5-1 | 2.87k | $0 | M | −8.7% | 08/19 | 08/17 | |
| AVTX | Sullivan Christopher Ryan | CFO | exercise10b5-1 | 37.9k | $0 | M | −8.7% | 08/19 | 08/17 | |
| AVTX | Sullivan Christopher Ryan | CFO | sale10b5-1 | 31.0k | -$62.2M | S | −8.7% | 08/19 | 08/18 | |
| AVTX | Sullivan Christopher Ryan | CFO | exercise10b5-1 | 31.0k | $30.6M | M | −8.7% | 08/19 | 08/18 | |
| AVTX | Sullivan Christopher Ryan | CFO | sale10b5-1 | 3.74k | -$7.47M | S | −8.7% | 08/19 | 08/17 | |
| AVTX | Sullivan Christopher Ryan | CFO | sale10b5-1 | 37.9k | -$75.3M | S | −8.7% | 08/19 | 08/17 | |
| AVTX | Sullivan Christopher Ryan | CFO | exercise10b5-1 | 2.87k | $2.84M | M | −8.7% | 08/19 | 08/17 | |
| AVTX | Sullivan Christopher Ryan | CFO | exercise10b5-1 | 37.9k | $37.4M | M | −8.7% | 08/19 | 08/17 | |
| AVTX | Doyle Mittie | CMO | exercise10b5-1 | 1.00k | $0 | M | −8.7% | 08/19 | 08/17 | |
| AVTX | Doyle Mittie | CMO | sale10b5-1 | 1.00k | -$2.00M | S | −8.7% | 08/19 | 08/17 | |
| AVTX | Doyle Mittie | CMO | exercise10b5-1 | 1.00k | $1.26M | M | −8.7% | 08/19 | 08/17 |
Avalo Therapeutics, Inc. Insider Activity FAQ
SEC Form 4 contextWho recently reported transactions at Avalo Therapeutics, Inc.?
Doyle Mittie, Sullivan Christopher Ryan.
When was the latest reported open-market purchase?
No code-P purchase is available for this period.
When was the latest reported open-market sale?
Doyle Mittie reported a sale on Aug 28, 2026 valued at $1.35M. Read the SEC filing.
What is the recent purchase and sale balance?
Net open-market selling in the selected period was $1,483,999.25. Sales can occur for many non-investment reasons.
Where can I see the original SEC filing?
Every transaction row and latest-activity fact links to its original SEC filing.
What do these Form 4 transaction codes mean?
P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.